Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia - Authors' reply
Lancet Infect Dis
.
2020 Jan;20(1):20-21.
doi: 10.1016/S1473-3099(19)30717-0.
Authors
Marin H Kollef
1
,
Álvaro Réa-Neto
2
,
Richard G Wunderink
3
,
Christopher J Bruno
4
,
Elizabeth G Rhee
5
Affiliations
1
Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, MO, USA.
2
Departamento de Clínica Médica, Universidade Federal do Paraná, Curitiba, Brazil.
3
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
4
Merck & Co, Rahway, NJ 07065, USA.
5
Merck & Co, Rahway, NJ 07065, USA. Electronic address: elizabeth.rhee@merck.com.
PMID:
31876489
DOI:
10.1016/S1473-3099(19)30717-0
No abstract available
Publication types
Letter
Comment
MeSH terms
Cephalosporins
Cross Infection*
Doripenem
Double-Blind Method
Humans
Meropenem
Pneumonia, Ventilator-Associated*
Tazobactam
Substances
Cephalosporins
ceftolozane
Doripenem
Meropenem
Tazobactam